Feramda Biopharmaceutical

Company Overview

Snapshot

Founded in January 2017 by Prof. Benjamin Sredni and Joseph R. Ferencz, M.D., Feramda Biopharmaceutical operates with 1–10 employees. The company has secured funding across one round from one investor. In December 2018, Feramda Biopharmaceutical completed a Seed funding round.

Business overview

Feramda Biopharmaceutical is a Health Tech & Life Sciences company focused on developing tellurium-based oral drugs. Its core technology aims to treat wet age-related macular degeneration by reducing the need for intravitreal anti-vascular endothelial growth factor injections. The company's innovative approach involves tellurium-based molecules that inhibit angiogenesis through a unique mechanism, increasing angiogenesis inhibitors in the eye and reducing inflammation. Feramda Biopharmaceutical operates within the Pharmaceuticals, Drugs Discovery & Development, and Life Sciences sectors, targeting the healthcare and life sciences markets.

Company Intelligence Q&A

What is Feramda Biopharmaceutical's primary focus?

Feramda Biopharmaceutical develops tellurium-based oral drugs for treating wet age-related macular degeneration, aiming to reduce the frequency of intravitreal anti-vascular endothelial growth factor injections.

When was Feramda Biopharmaceutical founded?

Feramda Biopharmaceutical was founded in January 2017.

Who are the founders of Feramda Biopharmaceutical?

The company was co-founded by Prof. Benjamin Sredni and Joseph R. Ferencz, M.D.

What is the current operational status of Feramda Biopharmaceutical?

Feramda Biopharmaceutical ceased to operate in June 2022.

What was the last funding event for Feramda Biopharmaceutical?

In December 2018, Feramda Biopharmaceutical completed a Seed funding round with investment from ATOORO Fund.